本报告导读:RC48 联合疗法治疗1L 胃癌数据纳入ASCO 口头报告,值得期待。泰它西普gMGIII 期数据优异、安全性良好,有望25H1获批并参与医保谈判,看好研发持续兑现。投资要点:RC48 联合疗法1L 胃癌纳入2025 ASCO口头汇报,看好其治疗潜力。本次ASCO 会议上将读出包括维迪西妥单抗联合疗法1L 治疗HER2 表达胃癌、联合RC148(PD-1/VEGF 双抗)1L 治疗三...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.